Ambien

Ambien. It is a prescription medication primarily used for the short-term treatment of insomnia, specifically difficulties with sleep initiation. Marketed by Sanofi under the brand name Ambien, its active ingredient is the non-benzodiazepine hypnotic zolpidem. The drug acts rapidly by modulating GABA receptors in the central nervous system to promote sedation, though its pharmacological profile differs from traditional benzodiazepines.

Medical uses

It is indicated for the short-term management of insomnia characterized by difficulties with falling asleep. Clinical guidelines, such as those from the American Academy of Sleep Medicine, often recommend it as a treatment option due to its efficacy in reducing sleep latency. Prescribing is typically limited to a few weeks to minimize risks of tolerance and dependence. It is available in immediate-release and extended-release formulations, with the latter marketed as Ambien CR for helping maintain sleep. Use is generally not recommended for individuals with a history of substance abuse or severe hepatic impairment.

Adverse effects

Common side effects include dizziness, diarrhea, and drowsiness. More concerning are complex sleep-related behaviors, such as sleepwalking, sleep driving, and preparing and eating food while not fully awake, which have been reported to the Food and Drug Administration. Other serious risks include next-day impairment, anterograde amnesia, and in rare cases, severe allergic reactions. The European Medicines Agency has issued warnings regarding reduced driving ability the morning after use. Concurrent use with other central nervous system depressants, like alcohol or opioids, significantly increases the risk of respiratory depression and death.

Pharmacology

It functions as a positive allosteric modulator selective for the GABA_A receptor complex, specifically binding to the omega-1 receptor subunit. This binding potentiates the inhibitory effects of the neurotransmitter GABA, leading to neuronal hyperpolarization and sedation. Its selectivity is believed to contribute to its primary hypnotic effect with less pronounced anxiolytic, muscle relaxant, and anticonvulsant properties compared to benzodiazepines. It is metabolized primarily in the liver via the cytochrome P450 system, mainly by the CYP3A4 isoenzyme, and has a relatively short elimination half-life of approximately 2.5 hours.

Society and culture

The drug has had a significant presence in popular culture, often referenced in media for its potent sedative effects. Notable figures, including Roseanne Barr and Tiger Woods, have publicly discussed their use of the medication. High-profile incidents, such as the 2009 Hudson River ditching of US Airways Flight 1549, involved a co-pilot who had used it, though investigators from the National Transportation Safety Board did not cite it as a causal factor. Its potential for misuse and diversion has led to increased regulatory scrutiny, with the Drug Enforcement Administration classifying it as a Schedule IV controlled substance under the Controlled Substances Act.

History

The compound was first synthesized in the 1980s by researchers at the French pharmaceutical company Synthélabo, which later became part of Sanofi. It received approval from the Food and Drug Administration for use in the United States in 1992. Following patent expiration, numerous generic versions entered the market, significantly increasing its availability. In 2007, the FDA mandated stronger label warnings regarding complex sleep behaviors. A 2013 FDA requirement lowered the recommended starting dose for women, citing slower metabolism and higher blood levels based on data from the Scripps Research Institute.

Category:Drugs